Environmental

LEGN’s high R&D intensity versus revenue suggests a science-led operating model, which is generally more resource-efficient than peers with heavier manufacturing footprints.

The company’s capital allocation appears less emissions-intensive than industrial peers because value creation is concentrated in research rather than energy- and materials-heavy production.

No material environmental controversies were provided, so relative environmental positioning appears supported by a lower direct operational footprint than many biotech peers.

Environmental risk remains tied to laboratory and supply-chain practices, but these are typically less structurally burdensome than the physical-transition exposure seen in broader healthcare manufacturing.

Social

LEGN’s R&D-heavy model supports a highly skilled workforce profile, which is generally more favorable than peers reliant on larger, lower-skill operational labor bases.

Stock-based compensation at 3.0% of revenue indicates moderate dilution pressure, but it is not unusually high versus innovative biotech peers that commonly use equity incentives.

The absence of provided controversy data limits evidence of social weakness, and the company’s profile appears broadly aligned with peer norms in patient and employee stakeholder management.

Social execution risk is concentrated in talent retention and clinical-development conduct, yet these are standard industry risks rather than a clear relative disadvantage.

Governance

Debt-to-equity of 0.40 and net debt-to-EBITDA of 1.42 indicate moderate leverage, which is generally more conservative than peers with aggressive balance-sheet risk.

R&D spending at 35.0% of revenue suggests disciplined reinvestment into core science, which can support governance quality when capital allocation remains focused and transparent.

Stock-based compensation at 3.0% of revenue is manageable relative to many growth-stage biotech peers, limiting but not eliminating shareholder-alignment concerns.

No major governance controversies were provided, so the main governance question is execution discipline rather than a structural weakness versus peers.

Overall Score

LEGN appears to be positioned above average on ESG versus peers, led by a research-intensive operating model and moderate leverage, with no provided evidence of major controversies.

Score Driver: Research-Led Business Model With Moderate Balance-Sheet Risk